GRACEcast (treatments-and-support-video)
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Dr. Craig L. Slingluff, University of Virginia, discusses novel approaches to immunotherapy, including adoptive T-cell therapy, personalized cancer vaccines and personalized selection of immune therapies.


Dr. Mario Sznol, Yale School of Medicine, provides a detailed description of the mechanism of action of immunotherapy agents and discusses early data on the use of combination therapies.


Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melanoma.


Dr. Mario Sznol, Yale School of Medicine, provides an overview of melanoma and its treatment, and discusses current melanoma immunotherapies and other agents under investigation.


Dr. Julie Brahmer, Johns Hopkins University, discusses immunotherapies for NSCLC and SCLC, analyzes the relevant trial data and addresses the unique side effects of these therapies.


Dr. James Gulley, National Cancer Institute, discusses immunotherapies for genitourinary cancers, including recent trial results. He also addresses early data which may indicate that using immunotherapy sooner may benefit patients.


Terrie Schmith, a stage IV melanoma survivor, describes her battle with the disease and her successful treatment with pembrolizumab.


Dr. Evan J. Lipson, Johns Hopkins University, discusses the incidence and treatment of side effects of immunotherapy and compares them to chemotherapy toxicities.


Dr. Michael Atkins, Georgetown-Lombardi Comprehensive Cancer Center, details the positive trial results for immunotherapy in a wide variety of cancers. He also describes current trials of combination regimens and the future of immunotherapy.


Dr. James Gulley, National Cancer Institute, gives an overview of the immune system and describes the mechanism of action of immunotherapy agents, as well as results from clinical trials.